Participated · Series C · Sep 2025

Octave Bioscience is a commercial-stage precision care company whose flagship product is the Octave MSDA test, a multi-analyte blood-based assay for monitoring MS disease activity. The company reports broad physician adoption with over 325 prescribers, more than 19,000 patient tests delivered to date, and in-network reimbursement covering over 75 million contracted lives at favorable rates. Proceeds from the recent financings will support continued commercialization of the MSDA test and advancement of the company’s Parkinson’s disease pipeline. Octave describes its platform as providing quantitative, clinically actionable insights to improve disease monitoring and treatment decisions. The company also notes a partnership with the Michael J. Fox Foundation on Parkinson’s disease efforts. Octave is based in Menlo Park, Calif. Octave Bioscience is a commercial-stage precision-medicine company that delivers a Precision Care Solution for multiple sclerosis and other neurodegenerative diseases. Its solution includes the Octave MSDA Test, a multivariate blood test for multiple sclerosis, enhanced MRI analytics and protocols, and a clinical care program that connects patients with MS-certified nurse care partners. The Precision Care Solution is currently in use in over 50 clinics across the United States. Octave plans to expand its biomarker-based approach into Parkinson’s disease and will use a $10M grant from The Michael J. Fox Foundation to discover, develop, and validate a custom multiplexed protein biomarker panel to measure Parkinson’s disease activity and progression in the clinic. The company was selected for the MJFF grant based on its track record in biomarker research and prior commercialization of a multiplexed assay panel for multiple sclerosis. Octave combines blood biomarkers, imaging, and clinical insights to provide longitudinal and holistic patient metrics intended to enable informed care, shared decision making, and better patient outcomes. Octave offers a multimodal precision care solution that combines blood biomarkers, expanded MRI analytics, and clinical insights to objectively measure MS disease activity, progression, and severity. Its platform includes the first multivariate blood test for MS disease activity, enhanced imaging protocols, and a clinical care program linking patients with MS nurse practitioners in real time. Octave commercially launched in late 2022 and is in use at multiple MS Centers of Excellence, academic centers, and high-volume independent clinics. The company is expanding physician partnerships and providing capabilities to pharma companies and health plans. Octave is also committed to building collaborations across a broader range of neurodegenerative diseases, including Parkinson’s and Alzheimer’s. Financially, the company announced a $30M extension to its Series B to accelerate commercialization and broaden patient access to its solution. Octave Bioscience is developing a Comprehensive Care Platform to provide a quantitative, objective measurement system designed to expand clinical insights in neurodegenerative disease, beginning with multiple sclerosis (MS). The platform integrates multiple layers of insight: blood-based biomarkers to assess inflammation and immune modulation, advanced MRI readings and interpretation for CNS-level insights, and real-time symptom tracking via mobile tools, sensors and wearables. All data are integrated into protocols, supported by decision‑support tools and presented in a dashboard that enables individual and population views for better stratification and contextual interventions. Octave plans to use these capabilities to provide measurement and management tools for physicians and precision tools and services for pharmaceutical companies to better characterize therapies and optimize pipeline programs. The company emphasizes longitudinal perspectives on disease progression and aims to expand the platform’s applicability across a broad range of neurodegenerative diseases. Octave is headquartered in Menlo Park, California. Octave Bioscience is completing development of a comprehensive, first-in-class care management platform for neurodegenerative disease, beginning with multiple sclerosis. The platform integrates blood-based biomarkers, enhanced MRI insights, patient monitoring via mobile tools and sensors, and a nurse-led care partner program to produce objective, quantitative measurements. Those measurement layers feed into care pathway models, analytical support systems, decision-support tools and a dashboard to provide longitudinal, population and individual views for clinicians. Octave plans to expand clinical data, initiate early commercial activities, and begin serving neurologists, MS patients and health plans. The company highlights potential application beyond MS to Parkinson’s disease, ALS and Alzheimer’s disease. Octave Bioscience is headquartered in Menlo Park, California.

Participated · Series C · Apr 2025

Biolinq is a healthcare technology company developing precision intradermal biosensors to improve metabolic health. Its initial product is a wearable biosensor patch with an array of tiny electrochemical microsensors that measure glucose continuously just beneath the skin’s surface, providing real-time feedback via a color-changing indicator light on the upper forearm. The device is designed to combine glucose monitoring with activity and sleep information to support people with Type 2 diabetes not on insulin. Biolinq’s platform is positioned for future multi-analyte sensing capabilities and the company says it has spent the last decade developing the underlying technology. The company recently completed a US pivotal trial and submitted for regulatory review; its intradermal glucose sensor remains investigational and is not yet FDA cleared. A $100 million Series C will finance the company’s push from development toward commercial readiness as it pursues US regulatory approval; Biolinq is headquartered in San Diego. Biolinq develops a wearable patch that uses an array of tiny electrochemical microsensors placed in the intradermal space to measure glucose and relative activity from just beneath the skin surface. The device is designed for simplicity and user feedback, with an intuitive on-device display that notifies users when glucose is within or outside target ranges. Its sensor array is engineered for redundancy, reliability and multi-analyte capabilities without the use of introducer needles or bleeding. Biolinq describes the intradermal glucose sensor as investigational and not yet cleared or approved by the FDA. The company is headquartered in San Diego, CA. Proceeds from the completed financing will fund completion of a U.S. pivotal clinical trial this year and support a subsequent FDA submission. Biolinq is developing a wearable biosensor platform whose first product is a needle-free, intelligent continuous glucose sensor with a novel integrated display on the device. The device leverages semiconductor-industry innovation to miniaturize electrochemical sensors into a micro-array of miniature biosensors roughly 25 times smaller than conventional glucose sensors, enabling redundant measurements for reliability. Early feasibility studies demonstrated the microarray patch can track glucose continuously for up to seven days in people with diabetes. Biolinq’s approach includes multiplexed sensing capabilities and immediate biosensor feedback designed to simplify diabetes management and support future consumer health and wellness applications. The company is advancing clinical, regulatory, manufacturing and commercialization milestones to expand the sensing category. Financially, Biolinq completed a $100 million Series B financing, described as a record private capital raise in the continuous glucose monitoring space, with a broad syndicate of strategic and financial investors. Biolinq is developing a skin-applied, minimally-invasive electrochemical biosensor platform that analyzes interstitial fluid to provide actionable health information. Its first commercial product aims to let people with diabetes continuously monitor blood glucose without the pain and hassle of traditional continuous glucose monitoring systems. The platform is wirelessly enabled and designed to simultaneously measure multiple biomarkers, enabling a pipeline of biomonitoring products. Biolinq plans to use new financing to support growth of its technology platform and to fund additional clinical studies. The company completed its first clinical study in 2018 and reports promising initial clinical results. Biolinq was founded in 2012 and is located in San Diego. Biolinq develops a skin-applied, minimally-invasive electrochemical biosensor platform that analyzes biomarkers in interstitial fluid. Its wirelessly-enabled, nickel-sized biosensor patch is designed to continuously monitor multiple biomarkers and its first commercial product targets blood glucose monitoring without the pain and hassle of traditional CGM systems. The company emphasizes factory calibration (no finger sticks), low cost-of-goods, high manufacturing uniformity, and ease of use. Biolinq intends to leverage its novel manufacturing approach to increase access to CGM and simplify diabetes management. The platform’s ability to simultaneously measure multiple biomarkers supports plans to build a pipeline of additional biomonitoring products. Biolinq was founded in 2012 (as Electrozyme, LLC) and is located in San Diego.

Participated · Equity · May 2023

Prognos Health is a New York City–based real-world data (RWD) company operating a managed, integrated RWD marketplace. Its platform harmonizes lab and health records across more than 325 million de-identified patients to provide a comprehensive, integrated view of patient health. The marketplace is used by over 70 life sciences customers to accelerate drug development, improve the safety and efficacy of existing drugs, and identify new patient populations. Led by CEO Sundeep Bhan, Prognos serves researchers, payers, and providers with fully integrated datasets to support clinical and commercial decision-making. The company raised $23M in growth equity and intends to use the funds to accelerate growth and expand the reach of its platform. The article emphasizes the company’s focus on expanding its impact on healthcare through data-driven tools and partnerships. Medivo operates a HIPAA-compliant, cloud-based health monitoring platform that provides modules for physicians and patients across a range of conditions and offers mobile tools and simple explanations of lab results. The company provides free services for physicians and consumers and has expanded its reach with increased engagements with life sciences firms and a partnership with the American Association of Clinical Endocrinologists. Medivo reports having doubled its growth year-over-year for the past three years and has presented peer-reviewed findings from a proprietary clinical database. The platform includes modules for diabetes, dyslipidemia, hepatitis C, gout, low testosterone, irritable bowel disease, hereditary angioedema, chronic myelogenous leukemia and other conditions, with initiatives to add obesity, rheumatoid arthritis, hepatitis B, HIV, several cancers, and additional chronic diseases. The company plans to continue expanding its network of laboratories, enrich its analytics services, build connectivity to additional data sources, and broaden product offerings and patient engagement services. Medivo is New York City–based and is venture-backed by investors including Merck GHIF, Safeguard Scientifics, and MentorTech Ventures. Medivo provides data analytics and lab testing services through an online, HIPAA‑compliant platform that connects patients to a nationwide network of physicians, lab service centers, and home testing services. Its PatientPath™ services identify gaps in patient lab testing and treatment, enable testing through thousands of labs, explain results to patients, and relay information to primary care physicians. The platform is designed to improve access to testing, educate patients about results, and help physicians make more efficient use of diagnostic testing. Medivo’s stated mission is to save lives through faster and easier access to quality healthcare; the company is led by co‑founder and CEO Sundeep Bhan. The article positions Medivo to capitalize on a U.S. lab testing market described as more than $50 billion and expected to double by 2020, noting lab services affect roughly 70% of critical clinical decisions. The company announced a $7 million Series A to support product development and expansion of sales and marketing.

Participated · Series A · Mar 2022

Altoida’s core product is a precision neurology platform that uses AI to analyze a proprietary 10-minute set of digital test activities delivered via augmented reality on a smartphone or tablet to capture cognitive and functional changes. The AR-based tests simulate activities of daily living to detect Mild Cognitive Impairment and Alzheimer’s earlier and more accurately than existing methods; the platform has received FDA Breakthrough Device Designation. The company says its technology is intended to accelerate and improve drug development, research, and clinical care for neurological diseases and to validate applications across Parkinson’s and schizophrenia. Altoida plans to invest in medical, scientific, engineering, and commercial teams, and to expand its US and global intellectual property and regulatory portfolios. The platform is supported by more than 20 years of scientific research and aims to address the large and growing global burden of Alzheimer’s and related dementias. Altoida is based in Washington, D.C. Altoida develops an FDA-cleared and CE Mark–approved medical device and brain health data platform that uses AI, ML and AR to collect functional and cognitive digital biomarkers. The company leverages smart device sensors and interactive tasks (asking patients to hide and seek virtual objects) to analyze visuospatial and executive function and detect ‘‘micro-errors’’ as prognostic and diagnostic biomarkers. Altoida’s technology is used by researchers, patients and physicians to detect Mild Cognitive Impairment due to Alzheimer’s disease in patients 62+ years old between six and ten years prior to symptom onset. The platform and methodology have been validated in more than 12 peer-reviewed publications and over 200 independent studies. Altoida says the new financing will support expansion in the US, Japan, Europe and Brazil. The company is led by Dr. Richard Fischer and has offices in Houston, San Diego and Lucerne, Switzerland. Altoida develops an FDA-cleared and CE Mark-approved medical device and brain-health data platform that objectively assesses cognitive and everyday functions prior to symptom onset. Its product leverages artificial intelligence, machine learning and augmented reality to collect functional and cognitive biomarkers. The platform analyzes visuospatial and executive function through a battery of three tests that ask patients to hide and seek virtual objects in physical space. Altoida has been validated in more than 12 peer-reviewed publications and over 200 independent studies and is used in clinics across the US, Europe and Brazil. The company raised $6.3M in a Series A and intends to use the capital to expand its global presence with an immediate focus on commercialization in the US and EU markets. Altoida maintains offices in Houston, San Diego and Lucerne, Switzerland.

Led · Series B · Mar 2022

Altibbi is an AI-powered digital health platform based in Dubai, UAE, founded in 2011. It offers more than two million pages of Arabic medical content and provides 24/7 online medical consultations across the Arab world. The platform records over 20 million unique monthly visitors and about three million consultations a year. Led by founder and CEO Jalil Allabadi, Altibbi combines content, telemedicine and AI-driven services. The company plans to use new funding to accelerate growth and expand its footprint in Saudi Arabia and Egypt, and to move into online pharmacy and diagnostics to enhance its AI-based health services. Altibbi has raised more than US$50m in total funding since its founding. Altibbi provides connected health services and solutions across 10 markets in the Arab World, primarily delivered through its iOS and Android apps and online presence. Its health plans offer real-time, round-the-clock telehealth services and access to local primary-care doctors. The company maintains an Arabic medical content library of 1.5M pages and a free Q&A platform that answers about 1,000 daily questions via a directory of 12,000 verified Arab doctors. Led by founder and CEO Jalil Allabadi and co-founder and COO Ayman Sharaiha, Altibbi serves both consumers and businesses across MENA. The company raised $6.5M to expand its digital health offering for businesses and consumers, grow its Arabic content, and build on its Q&A services. The funding is intended to support product expansion and market growth across the region.